Patents Assigned to Bayer Aktiengesellschaft
  • Publication number: 20230159506
    Abstract: The present disclosure relates to thienyloxazolones and analogues thereof of formula (III) that may be used for protecting plants from bacterial diseases, in particular from bacterial diseases caused by bacteria belonging to the genus Xanthomonas.
    Type: Application
    Filed: July 3, 2019
    Publication date: May 25, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: David BERNIER, Stéphane BRUNET, Jérémy DUFOUR, Thomas KNOBLOCH, Lionel NICOLAS, Tomoki TSUCHIYA
  • Patent number: 11655258
    Abstract: The present invention relates to novel fused bicyclic heterocycle derivatives of formula (I) in which Aa, Ab, Ac, Ad and Q have the meanings mentioned above, agrochemical formulations containing the compounds of formula (I) and their use as acaricides and/or insecticides for controlling animal pests, particularly arthropods and especially insects and arachnids.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: May 23, 2023
    Assignee: Bayer Aktiengesellschaft
    Inventors: Dominik Hager, Ruediger Fischer, Laura Hoffmeister, Nina Kausch-Busies, Marc Mosrin, David Wilcke, Matthieu Willot, Kerstin Ilg, Ulrich Goergens, Andreas Turberg
  • Patent number: 11655297
    Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 23, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.
    Inventors: Lars Röse, Uwe Gritzan, Julia Hütter, Spencer Liang, Andrew Pow, John Hunter, Ofer Levy, Ilan Vaknin
  • Publication number: 20230150968
    Abstract: The present disclosure relates to substituted thiophene carboxamides derivatives, their use for controlling phytopathogenic microorganisms and compositions comprising thereof.
    Type: Application
    Filed: December 17, 2020
    Publication date: May 18, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Jeremy DUFOUR, Lionel NICOLAS, Thomas KNOBLOCH, Stephane BRUNET, Sybille LAMPRECHT
  • Publication number: 20230149553
    Abstract: The present invention relates to novel liquid pharmaceutical formulations, preferably for inhalation, comprising polyethylene glycol (PEG)-based prodrugs of Adrenomedullin (PEG-ADM) and the use thereof for the treatment and/or prevention of acute lung injury/acute respiratory distress syndrome (ALI/ARDS).
    Type: Application
    Filed: March 31, 2021
    Publication date: May 18, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Florian UNGER, Stefan Christian SCHNEID, Hans-Walter MOTZKUS, Carina HAASBACH
  • Publication number: 20230151442
    Abstract: A lysis buffer comprising one non-ionic surfactant is provided which can be used as a one-step reagent of the preparation, storage, amplification, and/or detection of nucleic acids. Various embodiments of the lysis buffer of the invention comprise other substances that are compatible or useful in lysing cells, storing nucleic acids, amplifying nucleic acids, purifying nucleic acids, detecting nucleic acids, and/or other procedures for analysis of nucleic acids. Methods and kits based on the lysis buffer are also provided, including those for rapid lysis of cells and direct use of the resulting cell lysates in RT-PCR.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 18, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Stefan GOLZ, Holger SUMMER, Silke AIGNER, Heidrun ELLINGER-ZIEGELBAUER, Kirsten LEINEWEBER, Thomas MÜLLER
  • Patent number: 11647750
    Abstract: The present invention relates to novel active compound combinations comprising at least one known compound of the formula (I) and at least one further active compound, which combinations are highly suitable for controlling animal and microbial pests such as unwanted insects and/or unwanted acarida and/or unwanted nematodes.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: May 16, 2023
    Assignee: Bayer Aktiengesellschaft
    Inventors: Silvia Cerezo-Galvez, Christian Marienhagen, Holger Weckwert, Wolfgang Thielert, Marita John
  • Publication number: 20230148194
    Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 11, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Norbert SCHMEES, Lars WORTMANN, DENNIS KIRCHHOFF, Thi Thanh Uyen NGUYEN, Nicolas WERBECK, Ulf BÖMER, Kirstin PETERSEN, Christina KOBER, Detlef STÖCKIGT, Christian LECHNER, Robin Michael MEIER, Simon Anthony HERBERT, Isabel Patrizia KERSCHGENS, DIRK KOSEMUND, Rienk OFFRINGA, Mareike GREES
  • Publication number: 20230139936
    Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: September 14, 2022
    Publication date: May 4, 2023
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Norbert SCHMEES, Ulrike ROEHN, Dennis KIRCHHOFF, Kirstin PETERSEN, Mareike GREES, Nicolas WERBECK, Benjamin BADER, Rienk OFFRINGA, Corinna LINK
  • Patent number: 11632958
    Abstract: Described is the use of compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram and a fungicide selected from the group of phosphonates, in particular fosetyl-aluminium for controlling Mosaic scab and reducing Venturia inequalis inoculum in apples, to a method for treating apple plants or apple plant parts for controlling Mosaic scab scab and reducing Venturia inequalis inoculum in apples and to a method for controlling Mosaic scab scab and reducing Venturia inequalis inoculum in plants and plant parts, in particular leaves by treating them with compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram and a fungicide selected from the group of phosphonates, in particular fosetyl-aluminium.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: April 25, 2023
    Assignee: Bayer Aktiengesellschaft
    Inventors: Sybille Lamprecht, Luk De Maeyer, Gilbert Labourdette
  • Publication number: 20230121195
    Abstract: The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 12, 2022
    Publication date: April 20, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Ilona GUTCHER, Ulrike RÖHN, Norbert SCHMEES, Ludwig ZORN, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Horst IRLBACHER, Michael PLATTEN
  • Publication number: 20230117034
    Abstract: The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 20, 2023
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BOEMER, Naomi BARAK, Philip LIENAU
  • Publication number: 20230115270
    Abstract: The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 13, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Lisa DIETZ, Magdalena PLATZK, Daniel MEIBOM, Philipp BUCHGRABER, Niels LINDNER, Eva Maria BECKER-PELSTER, Carsten SCHMECK
  • Publication number: 20230113037
    Abstract: The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 10, 2020
    Publication date: April 13, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Julien LEFRANC, Norbert SCHMEES, Ludwig ZORN, Robin Michael MEIER, Simon Anthony HERBERT, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Mátyás GORJÁNÁCZ, Christina KOBER, Bernd BUCHMANN, Stephan BÖHME, Ulrich BOTHE, Michael PLATTEN, Daniel BAUMANN
  • Publication number: 20230112499
    Abstract: The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and po
    Type: Application
    Filed: December 14, 2020
    Publication date: April 13, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Olaf PANKNIN, Frank SACHER, Nicole SCHMIDT, Gernot LANGER, Katrin NOWAK-REPPEL, Reinhard NUBBEMEYER, Sabine PILARI, Antje ROTTMANN, Hideki MIYATAKE ONDOZABAL, Holger SIEBENEICHER, Antonius TER LAAK, Hana CERNECKA
  • Publication number: 20230106032
    Abstract: The present invention provides compounds of general formula (I): in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: March 5, 2021
    Publication date: April 6, 2023
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BÖMER, Naomi BARAK, Philip LIENAU
  • Publication number: 20230100584
    Abstract: The invention relates to the development of formulations, preferably for biologically active substances. The aim of the invention is to provide a method, a computer system, and a computer program product for predicting at least one property of at least one formulation using a prediction model which has been trained to predict formulation properties by means of a monitored learning process using reference data.
    Type: Application
    Filed: February 18, 2021
    Publication date: March 30, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Holger DIEDAM, Johanna ANLAHR, Heike SKÖTSCH, Matthias ERBER
  • Patent number: 11613522
    Abstract: The invention relates to 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides of general formula (I) and to their agrochemically compatible salts (I) as well as to the use thereof in the field of plant protection.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 28, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer CropScience Aktiengesellschaft
    Inventors: Olaf Peters, Klaus Bernhard Haaf, Guido Bojack, Katherine Rose Law, Anu Bheemaiah Machettira, Hansjoerg Dietrich, Elmar Gatzweiler, Christopher Hugh Rosinger, Elisabeth Asmus
  • Publication number: 20230084899
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an AhR inhibitor, and component B being pembrolizumab or nivolumab. A further aspect of the present invention relates to combinations of three components, component A, component B, and component C; component A being an AhR inhibitor, component B being pembrolizumab or nivolumab, and component C being a further pharmaceutical agent. The present invention further relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment or prophylaxis of cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, kidney, head and neck, thyroid, parathyroid, and their distant metastases, lymphomas, sarcomas and leukemias.
    Type: Application
    Filed: December 14, 2020
    Publication date: March 16, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventor: Ilona GUTCHER
  • Publication number: 20230072245
    Abstract: The present disclosure relates to substituted thiophene carboxamides derivatives, their use for controlling phytopathogenic microorganisms and compositions comprising thereof.
    Type: Application
    Filed: December 17, 2020
    Publication date: March 9, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Jeremy DUFOUR, Thomas KNOBLOCH, Stephane BRUNET, Sybille LAMPRECHT